Washington University

The Council of the Queensland Institute of Medical Research

The Albert B. Sabin Vaccine Institute

Peter Hotez

Jeffrey Bethony

Gaddam Goud

Alexander Loukas

Maria Elena Bottazzi

Bin Zhan

Brian Jones

Susana Mendez

Aaron Miles

Mark Pearson

David Diemert

James Ashcom

Mahnaz Bdamchian

Ami Shah Brown

Yan Wang

John Hawdon

Peter Giacomautonio

Angela Williamson

A multivalent anthelmintic vaccine targets both hookworm and schistosomiasis. The vaccine includes, at a minimum, a recombinant third-stage larval hookworm antigen, a recombinant adult stage hookworm antigen, and a recombinant schistosome antigen. Preferably, the hookworm antigens areantigens, although antigens from other hookworm species (e.g.) may also be employed. The schistosome antigen is preferably aor aantigen although antigens from other schistosome species (e.g.) may also be employed. In some cases full or partial sequences of schistosome antigens may be fused with full or partial sequences of hookworm {) to produce recombinant chimeric antigens.

Multivalent antihelminthic vaccine

A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

Human hookworm vaccine

Preparations which elicit an immune response to hookworm antigens and which may be utilized as hookworm vaccines are provided. In addition, a method of increasing the effectiveness of vaccinations against infectious diseases in patients infected with hookworm is provided. The method involves chemically treating the hookworm infestation prior to administering the vaccine.

Hookworm vaccine

Growing community of inventors

Bethesda, MD, United States of America

Peter Hotez